The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults (NCT05761860) | Clinical Trial Compass
RecruitingEarly Phase 1
The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
United States45 participantsStarted 2023-09-12
Plain-language summary
Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.
Who can participate
Age range45 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Individuals fluent in English will participate.
* Must report some experience with opioids (e.g., oxycodone, defined as use at least once in the subject's lifetime).
* Be within 20% of their ideal body weight.
* Are not currently experiencing chronic pain (pain on most days during the past 3 months)
* Have a systolic blood pressure of \<=140 and diastolic blood pressure of \<= 90, and a heart rate \<= 90 beats per minute.
* Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.
Exclusion Criteria:
* Significant current physical disease or major (uncontrolled) psychiatric disorder.
* No self-reported current interest in drug abuse treatment.
* Women who are pregnant or nursing.
* Any severe comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.